March 3, 2009 - Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced that the U.S. FDA has cleared the Company’s Investigational New Drug application for its 131I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.
The details can be read here.
No comments:
Post a Comment